To report the first use of combined continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) in an extremely low birth weight (ELBW) infant, highlighting its clinical significance.
Key Findings:
Mean glucose level was 162 ± 57 mg/dL over 14 days, indicating significant glycemic control.
Time in target glucose range (62–180 mg/dL) was 59.4%, suggesting effective management.
CGM reduced invasive glucose measurements from 84–168 to 20, a reduction of 76%–88%, minimizing discomfort and risk.
Interpretation:
The case demonstrates the feasibility of sensor-augmented subcutaneous insulin pump therapy in an ELBW infant, providing a foundation for future closed-loop trials.
Limitations:
This is a single case report, limiting generalizability.
The off-label use of devices and medications may not reflect standard clinical practice.
Further studies are needed to validate findings in larger populations.
Conclusion:
This case establishes proof-of-concept for sensor-augmented subcutaneous insulin pump therapy in ELBW infants, with potential implications for future clinical practices and research.
A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.
